Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sallie K. Young"'
Autor:
Erica Penny-Peterson, Javier E. Banchs, Gerald V. Naccarelli, William R. Davidson, Mario D. Gonzalez, Deborah L. Wolbrette, Michelle J. Nickolaus, John Kelleman, Soraya Samii, Sallie K. Young, Jennifer Grando-Ting, Giselle A. Baquero
Publikováno v:
Congenital Heart Disease. 9:221-227
Background Atrial tachyarrhythmias (AT) including atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia represent a clinical challenge in the adult with congenital heart disease (CHD). Dofetilide (D) is a rapidly activating delayed r
Publikováno v:
Hospital Pharmacy. 47:712-720
Background Argatroban is a direct thrombin inhibitor used in the treatment of heparin-induced thrombocytopenia (HIT). No study has evaluated the safety and efficacy of a nurse-managed argatroban dosing protocol. Methods We performed a retrospective a
Autor:
Soraya Samii, Mario D. Gonzalez, Sallie K. Young, Gerald V. Naccarelli, Erica Penny-Peterson, Deborah L. Wolbrette, Javier E. Banchs, Giselle A. Baquero, Sondra Depalma
Publikováno v:
Journal of Cardiovascular Electrophysiology. 23:296-301
Dofetilide Reduces VT/VF and ICD Therapies. Background: Patients with an implanted cardioverter defibrillator (ICD) and ventricular arrhythmias leading to ICD therapies have poor clinical outcomes and quality of life. Antiarrhythmic agents and cathet
Autor:
Parag P. Patel, Soraya Samii, Sallie K. Young, Mario D. Gonzalez, Gerald V. Naccarelli, Javier E. Banchs, Erica Penny-Peterson, Deborah L. Wolbrette
Publikováno v:
Journal of Interventional Cardiac Electrophysiology. 23:111-115
Dofetilide, an IKr blocker has been demonstrated to be effective in terminating persistent atrial fibrillation and flutter (AF/AFL), and in maintaining sinus rhythm after direct current cardioversion (CV). It is not known, however, whether pharmacolo
Autor:
Kathleen A. Stringer, Ann K. Wittkowsky, Sarah A. Spinler, Marianne McCollum, Sallie K. Young
Publikováno v:
Pharmacotherapy. 27:36-40
Study Objective. To evaluate the level of agreement between two sets of criteria, the Thrombolysis in Myocardial Infarction (TIMI) criteria and investigator-developed criteria, for identifying bleeding events in patients who had undergone a percutane
Autor:
Sallie K. Young
Publikováno v:
Journal of Pharmacy Practice. 15:305-317
Heparin, in various forms, is used in a variety of conditions including prophylaxis and treatment of thromboembolic disorders. Although the most common adverse effect related to the use of heparin is bleeding, heparin-induced thrombocytopenia (HIT) c
Autor:
Sallie K. Young
Publikováno v:
Cancer Practice. 9:52-54
Autor:
Javier E, Banchs, Giselle A, Baquero, Michelle J, Nickolaus, Deborah L, Wolbrette, John J, Kelleman, Soraya, Samii, Jennifer, Grando-Ting, Erica, Penny-Peterson, William R, Davidson, Sallie K, Young, Gerald V, Naccarelli, Mario D, Gonzalez
Publikováno v:
Congenital heart disease. 9(3)
Atrial tachyarrhythmias (AT) including atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia represent a clinical challenge in the adult with congenital heart disease (CHD). Dofetilide (D) is a rapidly activating delayed rectifier po
Publikováno v:
Pharmacotherapy. 28(12)
Direct thrombin inhibitors are commonly used anticoagulants in patients with known or suspected heparin-induced thrombocytopenia (HIT). All three direct thrombin inhibitors available in the United States-argatroban, bivalirudin, and lepirudin-are pre
Autor:
Sallie K. Young
Publikováno v:
Cancer practice. 9(1)